Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DXM30Y
|
|||
| Drug Name |
LJPC-401
|
|||
| Drug Type |
Peptide
|
|||
| Indication | Beta thalassemia [ICD-11: 3A50.2; ICD-10: D56.1, D56.3] | Phase 2 | [1] | |
| Hemochromatosis [ICD-11: 5C64.1Y] | Phase 2 | [2] | ||
| Company |
La Jolla Pharmaceutical
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Hepcidin (HAMP) | Target Info | Agonist | [2] |
| WikiPathways | Iron metabolism in placenta | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03381833) A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Adult Patients With Transfusion-Dependent Beta Thalassemia. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT03395704) A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.